{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:21:05Z","timestamp":1792668065234,"version":"4.5.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T00:00:00Z","timestamp":1372377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s13346-013-0161-z","type":"journal-article","created":{"date-parts":[[2013,6,27]],"date-time":"2013-06-27T15:52:08Z","timestamp":1372348328000},"page":"74-83","source":"Crossref","is-referenced-by-count":180,"title":["Lipid nanoparticle delivery systems for siRNA-based therapeutics"],"prefix":"10.1007","volume":"4","author":[{"given":"C.","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. M.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. R.","family":"Cullis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,28]]},"reference":[{"issue":"6669","key":"161_CR1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806\u201311.","journal-title":"Nature"},{"issue":"6836","key":"161_CR2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494\u20138.","journal-title":"Nature"},{"key":"161_CR3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/1743-422X-8-276","volume":"8","author":"UA Ashfaq","year":"2011","unstructured":"Ashfaq UA et al. siRNAs: potential therapeutic agents against hepatitis C virus. Virol J. 2011;8:276.","journal-title":"Virol J"},{"issue":"1","key":"161_CR4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11095-007-9504-0","volume":"25","author":"Y Chen","year":"2008","unstructured":"Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. Pharm Res. 2008;25(1):72\u201386.","journal-title":"Pharm Res"},{"issue":"19","key":"161_CR5","doi-asserted-by":"crossref","first-page":"8800","DOI":"10.1073\/pnas.0912186107","volume":"107","author":"J DeVincenzo","year":"2010","unstructured":"DeVincenzo J et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107(19):8800\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"161_CR6","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nbt1122","volume":"23","author":"DV Morrissey","year":"2005","unstructured":"Morrissey DV et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23(8):1002\u20137.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"161_CR7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14712590903448158","volume":"10","author":"S Subramanya","year":"2010","unstructured":"Subramanya S et al. RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther. 2010;10(2):201\u201313.","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"161_CR8","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.cgt.7700931","volume":"13","author":"GR Devi","year":"2006","unstructured":"Devi GR. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 2006;13(9):819\u201329.","journal-title":"Cancer Gene Ther"},{"issue":"23","key":"161_CR9","doi-asserted-by":"crossref","first-page":"14849","DOI":"10.1073\/pnas.222406899","volume":"99","author":"LA Martinez","year":"2002","unstructured":"Martinez LA et al. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A. 2002;99(23):14849\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"161_CR10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1349-7006.2006.00234.x","volume":"97","author":"F Takeshita","year":"2006","unstructured":"Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer Sci. 2006;97(8):689\u201396.","journal-title":"Cancer Sci"},{"issue":"43","key":"161_CR11","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","volume":"104","author":"M DiFiglia","year":"2007","unstructured":"DiFiglia M et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007;104(43):17204\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"161_CR12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/156720107780362276","volume":"4","author":"MH Farah","year":"2007","unstructured":"Farah MH. RNAi silencing in mouse models of neurodegenerative diseases. Curr Drug Deliv. 2007;4(2):161\u20137.","journal-title":"Curr Drug Deliv"},{"key":"161_CR13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1465-9921-9-55","volume":"9","author":"T Li","year":"2008","unstructured":"Li T, Koshy S, Folkesson HG. RNA interference for CFTR attenuates lung fluid absorption at birth in rats. Respir Res. 2008;9:55.","journal-title":"Respir Res"},{"issue":"5","key":"161_CR14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1517\/14712590902926089","volume":"9","author":"G Courties","year":"2009","unstructured":"Courties G et al. RNA interference-based gene therapy for successful treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2009;9(5):535\u20138.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"161_CR15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/oli.2008.0164","volume":"18","author":"MA Behlke","year":"2008","unstructured":"Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides. 2008;18(4):305\u201319.","journal-title":"Oligonucleotides"},{"issue":"6","key":"161_CR16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.gt.3302703","volume":"13","author":"DM Dykxhoorn","year":"2006","unstructured":"Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006;13(6):541\u201352.","journal-title":"Gene Ther"},{"issue":"7089","key":"161_CR17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature04688","volume":"441","author":"TS Zimmermann","year":"2006","unstructured":"Zimmermann TS et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441(7089):111\u20134.","journal-title":"Nature"},{"issue":"3","key":"161_CR18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/mt.2011.294","volume":"20","author":"RL Kanasty","year":"2012","unstructured":"Kanasty RL et al. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther. 2012;20(3):513\u201324.","journal-title":"Mol Ther"},{"issue":"9","key":"161_CR19","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","volume":"9","author":"YL Chiu","year":"2003","unstructured":"Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA. 2003;9(9):1034\u201348.","journal-title":"RNA"},{"issue":"3","key":"161_CR20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/nat.2012.0361","volume":"22","author":"NM Snead","year":"2012","unstructured":"Snead NM, Rossi JJ. RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics. Nucleic Acid Ther. 2012;22(3):139\u201346.","journal-title":"Nucleic Acid Ther"},{"key":"161_CR21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0079-6107(68)90019-9","volume":"18","author":"AD Bangham","year":"1968","unstructured":"Bangham AD. Membrane models with phospholipids. Prog Biophys Mol Biol. 1968;18:29\u201395.","journal-title":"Prog Biophys Mol Biol"},{"issue":"1","key":"161_CR22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-2836(65)80093-6","volume":"13","author":"AD Bangham","year":"1965","unstructured":"Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238\u201352.","journal-title":"J Mol Biol"},{"issue":"5","key":"161_CR23","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1096\/fj.10-0503","volume":"24","author":"DW Deamer","year":"2010","unstructured":"Deamer DW. From \u201cbanghasomes\u201d to liposomes: a memoir of Alec Bangham, 1921\u20132010. FASEB J. 2010;24(5):1308\u201310.","journal-title":"FASEB J"},{"issue":"3","key":"161_CR24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/0014-5793(73)80394-1","volume":"36","author":"G Gregoriadis","year":"1973","unstructured":"Gregoriadis G. Drug entrapment in liposomes. FEBS Lett. 1973;36(3):292\u20136.","journal-title":"FEBS Lett"},{"issue":"14","key":"161_CR25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM197609302951406","volume":"295","author":"G Gregoriadis","year":"1976","unstructured":"Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med. 1976;295(14):765\u201370.","journal-title":"N Engl J Med"},{"issue":"13","key":"161_CR26","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJM197609232951305","volume":"295","author":"G Gregoriadis","year":"1976","unstructured":"Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J Med. 1976;295(13):704\u201310.","journal-title":"N Engl J Med"},{"issue":"5","key":"161_CR27","doi-asserted-by":"crossref","first-page":"58P","DOI":"10.1042\/bj1240058P","volume":"124","author":"G Gregoriadis","year":"1971","unstructured":"Gregoriadis G, Ryman BE. Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. Biochem J. 1971;124(5):58P.","journal-title":"Biochem J"},{"issue":"1","key":"161_CR28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/bi00829a048","volume":"8","author":"C Huang","year":"1969","unstructured":"Huang C. Studies on phosphatidylcholine vesicles. Formation and physical characteristics. Biochemistry. 1969;8(1):344\u201352.","journal-title":"Biochemistry"},{"issue":"17","key":"161_CR29","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1021\/bi00558a005","volume":"19","author":"SE Schullery","year":"1980","unstructured":"Schullery SE et al. Fusion of dipalmitoylphosphatidylcholine vesicles. Biochemistry. 1980;19(17):3919\u201323.","journal-title":"Biochemistry"},{"issue":"1","key":"161_CR30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1517\/17425247.5.1.25","volume":"5","author":"DB Fenske","year":"2008","unstructured":"Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv. 2008;5(1):25\u201344.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"161_CR31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0005-2736(85)90521-8","volume":"812","author":"MJ Hope","year":"1985","unstructured":"Hope MJ et al. Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta. 1985;812(1):55\u201365.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"161_CR32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0005-2736(86)90302-0","volume":"858","author":"LD Mayer","year":"1986","unstructured":"Mayer LD, Hope MJ, Cullis PR. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta. 1986;858(1):161\u20138.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"161_CR33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0005-2736(80)90558-1","volume":"601","author":"F Szoka","year":"1980","unstructured":"Szoka F et al. Preparation of unilamellar liposomes of intermediate size (0.1\u20130.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim Biophys Acta. 1980;601(3):559\u201371.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"161_CR34","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/0005-2736(73)90408-2","volume":"298","author":"S Batzri","year":"1973","unstructured":"Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta. 1973;298(4):1015\u20139.","journal-title":"Biochim Biophys Acta"},{"issue":"5555","key":"161_CR35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1126\/science.1066238","volume":"295","author":"AD Stroock","year":"2002","unstructured":"Stroock AD et al. Chaotic mixer for microchannels. Science. 2002;295(5555):647\u201351.","journal-title":"Science"},{"key":"161_CR36","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1038\/mtna.2012.28","volume":"1","author":"NM Belliveau","year":"2012","unstructured":"Belliveau NM et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids. 2012;1:e37.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"161_CR37","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1021\/la204833h","volume":"28","author":"IV Zhigaltsev","year":"2012","unstructured":"Zhigaltsev IV et al. Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir. 2012;28(7):3633\u201340.","journal-title":"Langmuir"},{"issue":"1","key":"161_CR38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/0005-2736(75)90038-3","volume":"406","author":"B Kruijff de","year":"1975","unstructured":"de Kruijff B, Cullis PR, Radda GK. Differential scanning calorimetry and 31P NMR studies on sonicated and unsonicated phosphatidylcholine liposomes. Biochim Biophys Acta. 1975;406(1):6\u201320.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"161_CR39","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0005-2736(76)90402-8","volume":"436","author":"B Kruijff De","year":"1976","unstructured":"De Kruijff B, Cullis PR, Radda GK. Outside\u2013inside distributions and sizes of mixed phosphatidylcholine\u2013cholesterol vesicles. Biochim Biophys Acta. 1976;436(4):729\u201340.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"161_CR40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-4157(97)00006-3","volume":"1331","author":"PR Cullis","year":"1997","unstructured":"Cullis PR et al. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta. 1997;1331(2):187\u2013211.","journal-title":"Biochim Biophys Acta"},{"key":"161_CR41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0076-6879(05)91001-X","volume":"391","author":"DB Fenske","year":"2005","unstructured":"Fenske DB, Cullis PR. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol. 2005;391:7\u201340.","journal-title":"Methods Enzymol"},{"issue":"1","key":"161_CR42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0009-3084(90)90131-A","volume":"53","author":"TD Madden","year":"1990","unstructured":"Madden TD et al. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids. 1990;53(1):37\u201346.","journal-title":"Chem Phys Lipids"},{"issue":"1","key":"161_CR43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0005-2736(86)90105-7","volume":"857","author":"LD Mayer","year":"1986","unstructured":"Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta. 1986;857(1):123\u20136.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"161_CR44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0005-2736(90)90091-2","volume":"1025","author":"LD Mayer","year":"1990","unstructured":"Mayer LD et al. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta. 1990;1025(2):143\u201351.","journal-title":"Biochim Biophys Acta"},{"issue":"21","key":"161_CR45","first-page":"5922","volume":"49","author":"LD Mayer","year":"1989","unstructured":"Mayer LD et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 1989;49(21):5922\u201330.","journal-title":"Cancer Res"},{"issue":"3","key":"161_CR46","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2010.02.029","volume":"144","author":"IV Zhigaltsev","year":"2010","unstructured":"Zhigaltsev IV et al. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release. 2010;144(3):332\u201340.","journal-title":"J Control Release"},{"issue":"1\u20132","key":"161_CR47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release Off Journal Control Release Soc. 2000;65(1\u20132):271\u201384.","journal-title":"J Control Release Off Journal Control Release Soc"},{"key":"161_CR48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","volume":"41","author":"H Maeda","year":"2001","unstructured":"Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzym Regul. 2001;41:189\u2013207.","journal-title":"Adv Enzym Regul"},{"issue":"12 Pt 1","key":"161_CR49","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387\u201392.","journal-title":"Cancer Res"},{"issue":"4","key":"161_CR50","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0002-9440(10)65006-7","volume":"156","author":"H Hashizume","year":"2000","unstructured":"Hashizume H et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156(4):1363\u201380.","journal-title":"Am J Pathol"},{"issue":"4","key":"161_CR51","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF00047468","volume":"6","author":"RK Jain","year":"1987","unstructured":"Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987;6(4):559\u201393.","journal-title":"Cancer Metastasis Rev"},{"key":"161_CR52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2040-2384-2-14","volume":"2","author":"H Sarin","year":"2010","unstructured":"Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res. 2010;2:14.","journal-title":"J Angiogenes Res"},{"key":"161_CR53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1479-5876-7-51","volume":"7","author":"H Sarin","year":"2009","unstructured":"Sarin H et al. Physiologic upper limit of pore size in the blood\u2013tumor barrier of malignant solid tumors. J Transl Med. 2009;7:51.","journal-title":"J Transl Med"},{"issue":"8","key":"161_CR54","first-page":"2949","volume":"36","author":"HK Kimelberg","year":"1976","unstructured":"Kimelberg HK et al. The effect of entrapment in liposomes on the in vivo distribution of [3H]methotrexate in a primate. Cancer Res. 1976;36(8):2949\u201357.","journal-title":"Cancer Res"},{"issue":"1","key":"161_CR55","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1432-1033.1974.tb03681.x","volume":"47","author":"G Gregoriadis","year":"1974","unstructured":"Gregoriadis G, Neerunjun DE. Control of the rate of hepatic uptake and catabolism of liposome-entrapped proteins injected into rats. Possible therapeutic applications. Eur J Biochem. 1974;47(1):179\u201385.","journal-title":"Eur J Biochem"},{"issue":"3","key":"161_CR56","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0006-291X(75)80433-5","volume":"63","author":"RL Juliano","year":"1975","unstructured":"Juliano RL, Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun. 1975;63(3):651\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"161_CR57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0005-2736(79)90357-2","volume":"551","author":"D Hoekstra","year":"1979","unstructured":"Hoekstra D, Scherphof G. Effect of fetal calf serum and serum protein fractions on the uptake of liposomal phosphatidylcholine by rat hepatocytes in primary monolayer culture. Biochim Biophys Acta. 1979;551(1):109\u201321.","journal-title":"Biochim Biophys Acta"},{"issue":"26","key":"161_CR58","doi-asserted-by":"crossref","first-page":"18759","DOI":"10.1016\/S0021-9258(19)37026-7","volume":"267","author":"A Chonn","year":"1992","unstructured":"Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem. 1992;267(26):18759\u201365.","journal-title":"J Biol Chem"},{"issue":"3","key":"161_CR59","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0005-2736(89)90306-4","volume":"984","author":"SM Moghimi","year":"1989","unstructured":"Moghimi SM, Patel HM. Differential properties of organ-specific serum opsonins for liver and spleen macrophages. Biochim Biophys Acta. 1989;984(3):379\u201383.","journal-title":"Biochim Biophys Acta"},{"issue":"24","key":"161_CR60","doi-asserted-by":"crossref","first-page":"11460","DOI":"10.1073\/pnas.88.24.11460","volume":"88","author":"D Papahadjopoulos","year":"1991","unstructured":"Papahadjopoulos D et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991;88(24):11460\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"161_CR61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0005-2736(91)90201-I","volume":"1068","author":"TM Allen","year":"1991","unstructured":"Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1991;1068(2):133\u201341.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"161_CR62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-3659(02)00462-5","volume":"88","author":"T Ishida","year":"2003","unstructured":"Ishida T et al. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release. 2003;88(1):35\u201342.","journal-title":"J Control Release"},{"issue":"9","key":"161_CR63","first-page":"2431","volume":"52","author":"TM Allen","year":"1992","unstructured":"Allen TM et al. Stealth liposomes: an improved sustained release system for 1-beta-d-arabinofuranosylcytosine. Cancer Res. 1992;52(9):2431\u20139.","journal-title":"Cancer Res"},{"issue":"2","key":"161_CR64","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ijc.2910510221","volume":"51","author":"EG Mayhew","year":"1992","unstructured":"Mayhew EG et al. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int J Cancer. 1992;51(2):302\u20139.","journal-title":"Int J Cancer"},{"issue":"6","key":"161_CR65","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/ijc.2910510618","volume":"51","author":"J Vaage","year":"1992","unstructured":"Vaage J et al. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer. 1992;51(6):942\u20138.","journal-title":"Int J Cancer"},{"issue":"4","key":"161_CR66","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0925-4439(92)90010-K","volume":"1138","author":"IA Bakker-Woudenberg","year":"1992","unstructured":"Bakker-Woudenberg IA et al. Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. Biochim Biophys Acta. 1992;1138(4):318\u201326.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"161_CR67","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0936-6555(05)80269-9","volume":"6","author":"ND James","year":"1994","unstructured":"James ND et al. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi\u2019s sarcoma in AIDS. Clin Oncol (R Coll Radiol). 1994;6(5):294\u20136.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"Suppl 4","key":"161_CR68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2165\/00003495-199700544-00006","volume":"54","author":"FM Muggia","year":"1997","unstructured":"Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs. 1997;54 Suppl 4:22\u20139.","journal-title":"Drugs"},{"issue":"1","key":"161_CR69","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3816\/CLML.2011.n.005","volume":"11","author":"J Blade","year":"2011","unstructured":"Blade J et al. Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk. 2011;11(1):44\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"161_CR70","first-page":"2830","volume":"54","author":"NL Boman","year":"1994","unstructured":"Boman NL et al. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 1994;54(11):2830\u20133.","journal-title":"Cancer Res"},{"issue":"2","key":"161_CR71","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0005-2736(93)90256-Y","volume":"1152","author":"NL Boman","year":"1993","unstructured":"Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta. 1993;1152(2):253\u20138.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"161_CR72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF00686017","volume":"33","author":"LD Mayer","year":"1993","unstructured":"Mayer LD et al. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol. 1993;33(1):17\u201324.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"161_CR73","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s002800050846","volume":"42","author":"MS Webb","year":"1998","unstructured":"Webb MS et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin\/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol. 1998;42(6):461\u201370.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"161_CR74","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/bjc.1995.430","volume":"72","author":"MS Webb","year":"1995","unstructured":"Webb MS et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995;72(4):896\u2013904.","journal-title":"Br J Cancer"},{"issue":"1","key":"161_CR75","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36\u201348.","journal-title":"Adv Drug Deliv Rev"},{"issue":"21","key":"161_CR76","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1073\/pnas.84.21.7413","volume":"84","author":"PL Felgner","year":"1987","unstructured":"Felgner PL et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A. 1987;84(21):7413\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6205","key":"161_CR77","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/337387a0","volume":"337","author":"PL Felgner","year":"1989","unstructured":"Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature. 1989;337(6205):387\u20138.","journal-title":"Nature"},{"issue":"15","key":"161_CR78","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.gt.3301506","volume":"8","author":"IM Hafez","year":"2001","unstructured":"Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 2001;8(15):1188\u201396.","journal-title":"Gene Ther"},{"issue":"14","key":"161_CR79","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2174\/0929867033457412","volume":"10","author":"A Hirko","year":"2003","unstructured":"Hirko A, Tang F, Hughes JA. Cationic lipid vectors for plasmid DNA delivery. Curr Med Chem. 2003;10(14):1185\u201393.","journal-title":"Curr Med Chem"},{"issue":"3","key":"161_CR80","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2174\/1381612053382133","volume":"11","author":"B Martin","year":"2005","unstructured":"Martin B et al. The design of cationic lipids for gene delivery. Curr Pharm Des. 2005;11(3):375\u201394.","journal-title":"Curr Pharm Des"},{"issue":"8","key":"161_CR81","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1023\/A:1018932714745","volume":"11","author":"K Lappalainen","year":"1994","unstructured":"Lappalainen K et al. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res. 1994;11(8):1127\u201331.","journal-title":"Pharm Res"},{"issue":"2","key":"161_CR82","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0005-2736(97)00126-0","volume":"1329","author":"MC Filion","year":"1997","unstructured":"Filion MC, Phillips NC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta. 1997;1329(2):345\u201356.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"161_CR83","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0006-3495(01)76202-9","volume":"80","author":"N Maurer","year":"2001","unstructured":"Maurer N et al. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J. 2001;80(5):2310\u201326.","journal-title":"Biophys J"},{"issue":"1\u20132","key":"161_CR84","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0005-2736(00)00343-6","volume":"1510","author":"SC Semple","year":"2001","unstructured":"Semple SC et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta. 2001;1510(1\u20132):152\u201366.","journal-title":"Biochim Biophys Acta"},{"issue":"2\u20133","key":"161_CR85","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0169-409X(01)00103-X","volume":"47","author":"IM Hafez","year":"2001","unstructured":"Hafez IM, Cullis PR. Roles of lipid polymorphism in intracellular delivery. Adv Drug Deliv Rev. 2001;47(2\u20133):139\u201348.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5373","key":"161_CR86","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.281.5373.78","volume":"281","author":"I Koltover","year":"1998","unstructured":"Koltover I et al. An inverted hexagonal phase of cationic liposome\u2013DNA complexes related to DNA release and delivery. Science. 1998;281(5373):78\u201381.","journal-title":"Science"},{"issue":"2","key":"161_CR87","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","volume":"107","author":"J Heyes","year":"2005","unstructured":"Heyes J et al. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release. 2005;107(2):276\u201387.","journal-title":"J Control Release"},{"issue":"34","key":"161_CR88","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman M et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012;51(34):8529\u201333.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"161_CR89","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple SC et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172\u20136.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"161_CR90","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bbamem.2005.02.001","volume":"1669","author":"E Ambegia","year":"2005","unstructured":"Ambegia E et al. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta. 2005;1669(2):155\u201363.","journal-title":"Biochim Biophys Acta"},{"key":"161_CR91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0076-6879(02)46048-X","volume":"346","author":"DB Fenske","year":"2002","unstructured":"Fenske DB, MacLachlan I, Cullis PR. Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol. 2002;346:36\u201371.","journal-title":"Methods Enzymol"},{"issue":"2","key":"161_CR92","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.gt.3300821","volume":"6","author":"JJ Wheeler","year":"1999","unstructured":"Wheeler JJ et al. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther. 1999;6(2):271\u201381.","journal-title":"Gene Ther"},{"issue":"7","key":"161_CR93","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc A et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7):1357\u201364.","journal-title":"Mol Ther"},{"issue":"34","key":"161_CR94","doi-asserted-by":"crossref","first-page":"18440","DOI":"10.1021\/jp303267y","volume":"116","author":"AK Leung","year":"2012","unstructured":"Leung AK et al. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. J Phys Chem C Nanomater Interfaces. 2012;116(34):18440\u201350.","journal-title":"J Phys Chem C Nanomater Interfaces"},{"issue":"12","key":"161_CR95","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/mt.2011.190","volume":"19","author":"G Basha","year":"2011","unstructured":"Basha G et al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther. 2011;19(12):2186\u2013200.","journal-title":"Mol Ther"},{"issue":"5","key":"161_CR96","doi-asserted-by":"crossref","first-page":"E781","DOI":"10.1002\/ijc.27361","volume":"131","author":"JB Lee","year":"2012","unstructured":"Lee JB et al. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int J Cancer. 2012;131(5):E781\u201390.","journal-title":"Int J Cancer"},{"issue":"12","key":"161_CR97","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/mt.2011.142","volume":"19","author":"D Paolo Di","year":"2011","unstructured":"Di Paolo D et al. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol Ther. 2011;19(12):2201\u201312.","journal-title":"Mol Ther"},{"key":"161_CR98","unstructured":"World Gastroenterology Organisation global guideline. Hepatocellular carcinoma (HCC): a global perspective. http:\/\/www.worldgastroenterology.org\/assets\/downloads\/en\/pdf\/guidelines\/24_hepatocellular_carcinoma_en.pdf (2009)."},{"issue":"5441","key":"161_CR99","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.286.5441.971","volume":"286","author":"TU Mayer","year":"1999","unstructured":"Mayer TU et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999;286(5441):971\u20134.","journal-title":"Science"},{"issue":"7038","key":"161_CR100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature03503","volume":"435","author":"LC Kapitein","year":"2005","unstructured":"Kapitein LC et al. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature. 2005;435(7038):114\u20138.","journal-title":"Nature"},{"issue":"6","key":"161_CR101","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2144\/02336st01","volume":"33","author":"D Weil","year":"2002","unstructured":"Weil D et al. Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells. Biotechniques. 2002;33(6):1244\u20138.","journal-title":"Biotechniques"},{"issue":"2","key":"161_CR102","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/joim.12019","volume":"273","author":"L Claesson-Welsh","year":"2013","unstructured":"Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114\u201327.","journal-title":"J Intern Med"},{"issue":"5706","key":"161_CR103","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58\u201362.","journal-title":"Science"},{"issue":"1","key":"161_CR104","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1758-907X-1-16","volume":"1","author":"Y Landesman","year":"2010","unstructured":"Landesman Y et al. In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR). Silence. 2010;1(1):16.","journal-title":"Silence"},{"key":"161_CR105","volume-title":"Protein misfolding diseases: current and emerging principles and therapies","author":"SR Zeldenrust","year":"2010","unstructured":"Zeldenrust SR, Benson MD. Familial and senile amyloidosis caused by transthyretin. In: Ramirez-Alvarado M, Kelly JW, Dobson C, editors. Protein misfolding diseases: current and emerging principles and therapies. New York: Wiley; 2010."},{"key":"161_CR106","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/978-94-007-5416-4_21","volume":"65","author":"T Nagasaka","year":"2012","unstructured":"Nagasaka T. Familial amyloidotic polyneuropathy and transthyretin. Subcell Biochem. 2012;65:565\u2013607.","journal-title":"Subcell Biochem"},{"issue":"7","key":"161_CR107","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","volume":"336","author":"DR Jacobson","year":"1997","unstructured":"Jacobson DR et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in Black Americans. N Engl J Med. 1997;336(7):466\u201373.","journal-title":"N Engl J Med"},{"issue":"11","key":"161_CR108","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1517\/13543776.2010.518615","volume":"20","author":"M Abifadel","year":"2010","unstructured":"Abifadel M et al. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin Ther Pat. 2010;20(11):1547\u201371.","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"161_CR109","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","volume":"216","author":"B Cariou","year":"2011","unstructured":"Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis. 2011;216(2):258\u201365.","journal-title":"Atherosclerosis"},{"issue":"3","key":"161_CR110","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/11590330-000000000-00000","volume":"11","author":"M Farnier","year":"2011","unstructured":"Farnier M. The role of proprotein convertase subtilisin\/kexin type 9 in hyperlipidemia: focus on therapeutic implications. Am J Cardiovasc Drugs. 2011;11(3):145\u201352.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"161_CR111","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1096\/fj.04-2910fje","volume":"19","author":"S Reagan-Shaw","year":"2005","unstructured":"Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J. 2005;19(6):611\u20133.","journal-title":"FASEB J"},{"key":"161_CR112","doi-asserted-by":"crossref","unstructured":"Ramanathan RK, et al., A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, Abstract number LB-289, 6\u201310 April, Washington, DC; 2013.","DOI":"10.1158\/1538-7445.AM2013-LB-289"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-013-0161-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13346-013-0161-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-013-0161-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T15:59:51Z","timestamp":1645891191000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13346-013-0161-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,28]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["161"],"URL":"https:\/\/doi.org\/10.1007\/s13346-013-0161-z","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,28]]}}}